We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
Read MoreHide Full Article
Key Takeaways
Amgen, Bausch Health, CareDx and Centene are positioned as defensive healthcare stocks.
CareDx and Centene expect more than 100% earnings growth this year.
Earnings estimates improved for all four stocks over the past 60 days.
Inflation climbed again in August, after easing marginally over the past two months. The latest consumer price index (CPI) print released on Friday shows that the Federal Reserve has ample reasons to go for a rate hike after its September policy meeting next week.
Consumers are already struggling to pay as prices of goods and services are increasing. Oil prices have been on the rise again as tensions in the Middle East continue, pushing inflation even higher.
Markets have remained volatile for over three months now, and a rate hike is likely to make spending tougher for consumers. Given this scenario, we recommend buying four defensive stocks from the healthcare sector, namely, Amgen Inc. (AMGN - Free Report) , Bausch Health Companies Inc. (BHC - Free Report) , CareDx, Inc. (CDNA - Free Report) and Centene Corporation (CNC - Free Report) .
Inflation Continues to Climb
The CPI increased 0.4% sequentially in August, which came in line with analysts’ expectations, the Bureau of Labor Statistics said on Friday. The annual CPI rate came in at 3.4%, also in line with the consensus estimate.
Core CPI, which strips out the volatile food and energy, rose 0.3% sequentially in August, higher than the consensus estimate of a rise of 0.2%. Year over year, core CPI increased 2.4%, in line with economists’ expectations.
Although the readings matched the forecasts, inflation remained stubbornly high last month. Food prices rose 0.1% sequentially in August and 2.7% from the year-ago levels. Oil prices have primarily been responsible for the steep jump in inflation over the past few months.
As the United States and Iran continue to engage in attacks and counterattacks in the Middle East, consumers fear that tensions could continue for a prolonged period, which could push inflation higher.
Gasoline prices rose 3.9% in August, accounting for one-third of the CPI index’s rise. Year over year, energy prices are up 16.3%. Gasoline prices and fuel oil jumped 27.4% and 52%, respectively, from the year-ago levels.
The latest CPI print will be the final major inflation report the Federal Reserve will consider before its FOMC policy meeting next week. The central bank has struggled to tame inflation but has kept interest rates unchanged this year, in its current range of 3.5% to 3.75%.
However, a rate hike is now the only option left for the Federal Reserve to counter the challenge. Markets are pricing in a 90% chance of a quarter-percentage-point rate hike next week, according to the CME FedWatch tool.
4 Healthcare Stocks With Upside
Amgen
Amgen Inc. is one of the biggest biotech companies in the world, with a strong presence in the oncology, general medicine, inflammation and rare diseases markets. AMGN used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta.
Amgen has an expected earnings growth rate of 5% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3% over the past 60 days. AMGN currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company focused on developing, manufacturing and marketing products across key therapeutic areas such as gastroenterology, hepatology, neurology and dermatology. BHC’s portfolio includes branded and generic drugs, branded generics, over-the-counter (OTC) products and aesthetic medical devices.
Bausch Health Companies has an expected earnings growth rate of 16.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 7.4% over the past 60 days. BHC currently carries a Zacks Rank #2.
CareDx
CareDx, Inc. develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients. CDNA provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA as a biomarker for rejection.
CareDx’s expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for current-year earnings has improved 35.2% over the past 60 days. Currently, CDNA has a Zacks Rank #1.
Centene Corporation
Centene Corporation is a well-diversified healthcare company that primarily provides a set of services to government-sponsored healthcare programs, while serving underinsured and uninsured individuals through member-focused services. CNC is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene operates a capitated managed-care model. Under this model, it receives a fixed payment per member per month from government programs such as Medicaid, Medicare and ACA Marketplace plans.
Centene Corporation has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 40.9% over the past 60 days. CNC currently sports a Zacks Rank #1.
View the Zacks #1 Rank List
Image: Bigstock
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike
Key Takeaways
Inflation climbed again in August, after easing marginally over the past two months. The latest consumer price index (CPI) print released on Friday shows that the Federal Reserve has ample reasons to go for a rate hike after its September policy meeting next week.
Consumers are already struggling to pay as prices of goods and services are increasing. Oil prices have been on the rise again as tensions in the Middle East continue, pushing inflation even higher.
Markets have remained volatile for over three months now, and a rate hike is likely to make spending tougher for consumers. Given this scenario, we recommend buying four defensive stocks from the healthcare sector, namely, Amgen Inc. (AMGN - Free Report) , Bausch Health Companies Inc. (BHC - Free Report) , CareDx, Inc. (CDNA - Free Report) and Centene Corporation (CNC - Free Report) .
Inflation Continues to Climb
The CPI increased 0.4% sequentially in August, which came in line with analysts’ expectations, the Bureau of Labor Statistics said on Friday. The annual CPI rate came in at 3.4%, also in line with the consensus estimate.
Core CPI, which strips out the volatile food and energy, rose 0.3% sequentially in August, higher than the consensus estimate of a rise of 0.2%. Year over year, core CPI increased 2.4%, in line with economists’ expectations.
Although the readings matched the forecasts, inflation remained stubbornly high last month. Food prices rose 0.1% sequentially in August and 2.7% from the year-ago levels. Oil prices have primarily been responsible for the steep jump in inflation over the past few months.
As the United States and Iran continue to engage in attacks and counterattacks in the Middle East, consumers fear that tensions could continue for a prolonged period, which could push inflation higher.
Gasoline prices rose 3.9% in August, accounting for one-third of the CPI index’s rise. Year over year, energy prices are up 16.3%. Gasoline prices and fuel oil jumped 27.4% and 52%, respectively, from the year-ago levels.
The latest CPI print will be the final major inflation report the Federal Reserve will consider before its FOMC policy meeting next week. The central bank has struggled to tame inflation but has kept interest rates unchanged this year, in its current range of 3.5% to 3.75%.
However, a rate hike is now the only option left for the Federal Reserve to counter the challenge. Markets are pricing in a 90% chance of a quarter-percentage-point rate hike next week, according to the CME FedWatch tool.
4 Healthcare Stocks With Upside
Amgen
Amgen Inc. is one of the biggest biotech companies in the world, with a strong presence in the oncology, general medicine, inflammation and rare diseases markets. AMGN used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta.
Amgen has an expected earnings growth rate of 5% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3% over the past 60 days. AMGN currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bausch Health Companies
Bausch Health Companies Inc. is a global, diversified specialty pharmaceutical and medical device company focused on developing, manufacturing and marketing products across key therapeutic areas such as gastroenterology, hepatology, neurology and dermatology. BHC’s portfolio includes branded and generic drugs, branded generics, over-the-counter (OTC) products and aesthetic medical devices.
Bausch Health Companies has an expected earnings growth rate of 16.6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 7.4% over the past 60 days. BHC currently carries a Zacks Rank #2.
CareDx
CareDx, Inc. develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients. CDNA provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA as a biomarker for rejection.
CareDx’s expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for current-year earnings has improved 35.2% over the past 60 days. Currently, CDNA has a Zacks Rank #1.
Centene Corporation
Centene Corporation is a well-diversified healthcare company that primarily provides a set of services to government-sponsored healthcare programs, while serving underinsured and uninsured individuals through member-focused services. CNC is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene operates a capitated managed-care model. Under this model, it receives a fixed payment per member per month from government programs such as Medicaid, Medicare and ACA Marketplace plans.
Centene Corporation has an expected earnings growth rate of more than 100% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 40.9% over the past 60 days. CNC currently sports a Zacks Rank #1.